Latest Commercialisation News

RLF AgTech has appointed Stuart Upton as CEO, marking a strategic shift towards disciplined execution and commercial scaling of its crop nutrition and carbon platforms. Former Acting Managing Director Gavin Ball returns to Executive Director to focus on international expansion.

TG Metals has lodged a provisional patent application for a new technology that significantly improves lithium recovery and concentrate quality at its Burmeister deposit in Western Australia.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Murray Cod Australia announces the departure of CEO Ross Anderson, with interim leadership stepping in as the company searches for a new chief executive.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Provaris Energy has successfully completed the first phase of engineering design for a pioneering large-scale liquefied CO₂ tank, advancing carbon capture storage solutions with Yinson Production.

Impact Minerals has identified a promising standalone process to produce sulphate of potash and hydrochloric acid from lake clays in Western Australia, potentially reducing reliance on imports and addressing local industrial demand.

H3 Energy’s latest technical evaluation of the Warro 3 well reveals 11 promising dry gas zones, setting the stage for a targeted horizontal appraisal well to unlock commercial gas flow.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Livium Ltd announces a further A$335,000 distribution from its 50% stake in the LieNA joint venture, following receipt of a substantial R&D tax incentive rebate for FY25. The joint venture remains well-funded through FY27, supporting ongoing lithium extraction technology development.